StockData
Citius Pharmaceuticals, Inc. logo

Citius Pharmaceuticals, Inc. (CTXR) company profile

CTXRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 1/30
$0.52−0.01 (-1.67%)

Close on Nov 17, 2026Market cap $14.24MP/E –Yield –

About Citius Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of critical care therapeutic products. Its operations center on oncology, anti-infectives used in adjunct cancer care, and specialized prescription therapies. The company's portfolio features an approved oncology treatment, denileukin diftitox (marketed as LYMPHIR), for patients with persistent or recurrent cutaneous T-cell lymphoma. Additionally, its late-stage development pipeline includes Mino-Lok, an antibiotic lock solution engineered to salvage infected central venous catheters, Halo-Lido, a topical anti-inflammatory and anesthetic formulation for hemorrhoids, and a mesenchymal stem cell therapy for acute respiratory distress syndrome.

The company delivers its commercial therapies to adult patients diagnosed with persistent or recurrent cutaneous T-cell lymphoma. Its investigational treatments target hospitalized or outpatient individuals requiring catheter salvage or therapeutic relief for acute respiratory distress syndrome and hemorrhoids. Corporate headquarters and principal executive offices are located in Cranford, New Jersey.

Summary of the business section of Citius Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Citius Pharmaceuticals, Inc.
Founded
2007
Headquarters
Cranford, NJ
Address
11 Commerce Drive, 1st Floor 07016
Phone
(908) 967-6676
Employees
23, Sep 30, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Nevada
Fiscal year ends
September 30
Auditor
Wolf& Company, P.C., Boston, Massachusetts

Stock & identifiers

Ticker
CTXR
Exchange
Nasdaq
IPO date
Oct 2, 2014
Shares outstanding
27M, Aug 13, 2026
Public float
$11.39M, Mar 31, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-25 reverse, Nov 26, 2024; 1-for-15 reverse, Jun 9, 2017
SEC CIK
1506251
CUSIP
17322U306
ISIN
US17322U3068
FIGI
BBG001QQH2N3
Share class FIGI
BBG001V1J7S4
LEI
5493005C10W36P4KQP40
EIN
27-3425913

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Leonard L. MazurChief Executive Officer, Director410,214
Myron Z. HolubiakVice Chairman, Director79,690

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$4.51M$7.12M$2.48M$4–
FY2024$3.52M-$2.04M$1.97M$41–
FY2023$1.98M$6.29M$1.38M$57–
FY2022
Leonard Mazur
$1.19M$479.35K$848.42K$60–
FY2022
Myron Holubiak
$1.24M$529.35K$848.42K$60–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payTotalvs. prior year
Leonard Mazur
Chief Executive Officer and Executive Chairman
$475.00K$2.98M$820.44K$237.50K$4.51M+28%
Myron Holubiak
Executive Vice Chairman
$450.00K$1.49M$343.64K$225.00K$2.51M+14%
Dr. Myron Czuczman
Chief Medical Officer
$450.00K$1.44M$410.22K$157.50K$2.46M+46%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

Employees

Headcount reported in annual reports

“As of September 30, 2025, we had 23 employees”

Corporate history

Events identified from SEC filings

DateEventDetails
Aug 21, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 13, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 30, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 13, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 11, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 13, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 15, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 8, 2022DelistingNotice of delisting from exchange (Form 25)
Jul 10, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 7, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Feb 3, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 1, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 28, 2017ListingRegistration of securities on an exchange (Form 8-A)
May 17, 2016Late filingNotification of late filing
Apr 5, 2016Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 18, 2014Name changeName changed from Trail One, Inc. to Citius Pharmaceuticals, Inc.
Sep 18, 2014Auditor changeChange in certifying accountant (8-K Item 4.01)
Sep 18, 2014Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Feb 14, 2014Late filingNotification of late filing
Dec 31, 2013Late filingNotification of late filing
Aug 15, 2013Late filingNotification of late filing
Dec 31, 2012Late filingNotification of late filing
Aug 15, 2012Late filingNotification of late filing
Dec 29, 2011Late filingNotification of late filing

See a number that looks wrong?